P16 (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "P16" in English language version.

refsWebsite

Global rank English rank

76nih.gov

4^th place

51doi.org

2^nd place

16semanticscholar.org

11^th place

8^th place

8harvard.edu

18^th place

17^th place

2ensembl.org

1,626^th place

1,007^th place

2handle.net

102^nd place

76^th place

1omim.org

4,380^th place

4,305^th place

1nihr.ac.uk

low place

6,693^rd place

1pathologyoutlines.com

low place

1psu.edu

207^th place

136^th place

doi.org

Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA (April 1994). "Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers". Nature. 368 (6473): 753–756. Bibcode:1994Natur.368..753N. doi:10.1038/368753a0. PMID 8152487. S2CID 13199401.
Serrano M, Hannon GJ, Beach D (December 1993). "A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4". Nature. 366 (6456): 704–707. Bibcode:1993Natur.366..704S. doi:10.1038/366704a0. PMID 8259215. S2CID 4368128.
Roussel MF (September 1999). "The INK4 family of cell cycle inhibitors in cancer". Oncogene. 18 (38): 5311–5317. doi:10.1038/sj.onc.1202998. PMID 10498883.
Krishnamurthy J, Ramsey MR, Ligon KL, Torrice C, Koh A, Bonner-Weir S, et al. (September 2006). "p16INK4a induces an age-dependent decline in islet regenerative potential". Nature. 443 (7110): 453–457. Bibcode:2006Natur.443..453K. doi:10.1038/nature05092. PMID 16957737. S2CID 4402013.
Rayess H, Wang MB, Srivatsan ES (April 2012). "Cellular senescence and tumor suppressor gene p16". International Journal of Cancer. 130 (8): 1715–1725. doi:10.1002/ijc.27316. PMC 3288293. PMID 22025288.
Hara E, Smith R, Parry D, Tahara H, Stone S, Peters G (March 1996). "Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence". Molecular and Cellular Biology. 16 (3): 859–867. doi:10.1128/mcb.16.3.859. PMC 231066. PMID 8622687.
Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, et al. (November 2002). "Role of histone H3 lysine 27 methylation in Polycomb-group silencing". Science. 298 (5595): 1039–1043. Bibcode:2002Sci...298.1039C. doi:10.1126/science.1076997. PMID 12351676. S2CID 6265267.
Bracken AP, Kleine-Kohlbrecher D, Dietrich N, Pasini D, Gargiulo G, Beekman C, et al. (March 2007). "The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells". Genes & Development. 21 (5): 525–530. doi:10.1101/gad.415507. PMC 1820894. PMID 17344414.
Liggett WH, Sidransky D (March 1998). "Role of the p16 tumor suppressor gene in cancer". Journal of Clinical Oncology. 16 (3): 1197–1206. doi:10.1200/JCO.1998.16.3.1197. PMID 9508208.
Rocco JW, Sidransky D (March 2001). "p16(MTS-1/CDKN2/INK4a) in cancer progression". Experimental Cell Research. 264 (1): 42–55. doi:10.1006/excr.2000.5149. PMID 11237522.
Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, et al. (September 1994). "Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma". Nature Genetics. 8 (1): 27–32. doi:10.1038/ng0994-27. PMID 7726912. S2CID 23195660.
Bartsch D, Shevlin DW, Tung WS, Kisker O, Wells SA, Goodfellow PJ (November 1995). "Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas". Genes, Chromosomes & Cancer. 14 (3): 189–195. doi:10.1002/gcc.2870140306. PMID 8589035. S2CID 22823227.
Helgadottir H, Höiom V, Jönsson G, Tuominen R, Ingvar C, Borg A, et al. (August 2014). "High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families". Journal of Medical Genetics. 51 (8): 545–552. doi:10.1136/jmedgenet-2014-102320. PMC 4112445. PMID 24935963.
Igaki H, Sasaki H, Kishi T, Sakamoto H, Tachimori Y, Kato H, et al. (September 1994). "Highly frequent homozygous deletion of the p16 gene in esophageal cancer cell lines". Biochemical and Biophysical Research Communications. 203 (2): 1090–1095. doi:10.1006/bbrc.1994.2294. PMID 8093026.
Puig-Butille JA, Escámez MJ, Garcia-Garcia F, Tell-Marti G, Fabra À, Martínez-Santamaría L, et al. (March 2014). "Capturing the biological impact of CDKN2A and MC1R genes as an early predisposing event in melanoma and non melanoma skin cancer". Oncotarget. 5 (6): 1439–1451. doi:10.18632/oncotarget.1444. PMC 4039222. PMID 24742402.
Khor GH, Froemming GR, Zain RB, Abraham MT, Omar E, Tan SK, et al. (2013). "DNA methylation profiling revealed promoter hypermethylation-induced silencing of p16, DDAH2 and DUSP1 in primary oral squamous cell carcinoma". International Journal of Medical Sciences. 10 (12): 1727–1739. doi:10.7150/ijms.6884. PMC 3805925. PMID 24155659.
Demokan S, Chuang A, Suoğlu Y, Ulusan M, Yalnız Z, Califano JA, et al. (October 2012). "Promoter methylation and loss of p16(INK4a) gene expression in head and neck cancer". Head & Neck. 34 (10): 1470–1475. doi:10.1002/hed.21949. PMID 22106032. S2CID 11512476.
Shaw RJ, Liloglou T, Rogers SN, Brown JS, Vaughan ED, Lowe D, et al. (February 2006). "Promoter methylation of P16, RARbeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing". British Journal of Cancer. 94 (4): 561–568. doi:10.1038/sj.bjc.6602972. PMC 2361183. PMID 16449996.
Sharma G, Mirza S, Prasad CP, Srivastava A, Gupta SD, Ralhan R (April 2007). "Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients". Life Sciences. 80 (20): 1873–1881. doi:10.1016/j.lfs.2007.02.026. PMID 17383681.
Jabłonowski Z, Reszka E, Gromadzińska J, Wąsowicz W, Sosnowski M (June 2011). "Hypermethylation of p16 and DAPK promoter gene regions in patients with non-invasive urinary bladder cancer". Archives of Medical Science. 7 (3): 512–516. doi:10.5114/aoms.2011.23421. PMC 3258754. PMID 22295037.
Xu R, Wang F, Wu L, Wang J, Lu C (January 2013). "A systematic review of hypermethylation of p16 gene in esophageal cancer". Cancer Biomarkers. 13 (4): 215–226. doi:10.3233/CBM-130355. PMID 24240582.
Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. (July 2010). "Human papillomavirus and survival of patients with oropharyngeal cancer". The New England Journal of Medicine. 363 (1): 24–35. doi:10.1056/NEJMoa0912217. PMC 2943767. PMID 20530316.
Lydiatt WM, Patel SG, O'Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, et al. (March 2017). "Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual". CA. 67 (2): 122–137. doi:10.3322/caac.21389. PMID 28128848.
Mehanna H, Taberna M, von Buchwald C, Tous S, Brooks J, Mena M, et al. (March 2023). "Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis". The Lancet. Oncology. 24 (3): 239–251. doi:10.1016/s1470-2045(23)00013-x. hdl:2445/198366. PMID 36796393. S2CID 256860640.
"Testing for both HPV and p16 can give more precise prognoses in oropharyngeal (throat) cancer". NIHR Evidence. 2023. doi:10.3310/nihrevidence_59749. S2CID 261791439.
Oguejiofor KK, Hall JS, Mani N, Douglas C, Slevin NJ, Homer J, et al. (November 2013). "The prognostic significance of the biomarker p16 in oropharyngeal squamous cell carcinoma". Clinical Oncology. 25 (11): 630–638. doi:10.1016/j.clon.2013.07.003. PMID 23916365.
Balgkouranidou I, Liloglou T, Lianidou ES (February 2013). "Lung cancer epigenetics: emerging biomarkers". Biomarkers in Medicine. 7 (1): 49–58. doi:10.2217/bmm.12.111. PMID 23387484.
Sinha P, Thorstad WT, Nussenbaum B, Haughey BH, Adkins DR, Kallogjeri D, et al. (January 2014). "Distant metastasis in p16-positive oropharyngeal squamous cell carcinoma: a critical analysis of patterns and outcomes". Oral Oncology. 50 (1): 45–51. doi:10.1016/j.oraloncology.2013.10.007. PMC 3942323. PMID 24211084.
Hwang H, Tse C, Rodriguez S, Gown A, Churg A (May 2014). "p16 FISH deletion in surface epithelial mesothelial proliferations is predictive of underlying invasive mesothelioma". The American Journal of Surgical Pathology. 38 (5): 681–688. doi:10.1097/PAS.0000000000000176. PMID 24503757. S2CID 28068784.
Dreyer JH, Hauck F, Oliveira-Silva M, Barros MH, Niedobitek G (April 2013). "Detection of HPV infection in head and neck squamous cell carcinoma: a practical proposal". Virchows Archiv. 462 (4): 381–389. doi:10.1007/s00428-013-1393-5. PMID 23503925. S2CID 7469046.
Cioffi-Lavina M, Chapman-Fredricks J, Gomez-Fernandez C, Ganjei-Azar P, Manoharan M, Jorda M (July 2010). "P16 expression in squamous cell carcinomas of cervix and bladder". Applied Immunohistochemistry & Molecular Morphology. 18 (4): 344–347. doi:10.1097/PAI.0b013e3181d2bbd7. PMID 20571342. S2CID 5065484.
Hall BM, Balan V, Gleiberman AS, Strom E, Krasnov P, Virtuoso LP, et al. (July 2016). "Aging of mice is associated with p16(Ink4a)- and β-galactosidase-positive macrophage accumulation that can be induced in young mice by senescent cells". Aging. 8 (7): 1294–1315. doi:10.18632/aging.100991. PMC 4993332. PMID 27391570.
Liu Y, Sanoff HK, Cho H, Burd CE, Torrice C, Ibrahim JG, et al. (August 2009). "Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging". Aging Cell. 8 (4): 439–448. doi:10.1111/j.1474-9726.2009.00489.x. PMC 2752333. PMID 19485966.
Hernandez-Segura A, de Jong TV, Melov S, Guryev V, Campisi J, Demaria M (September 2017). "Unmasking Transcriptional Heterogeneity in Senescent Cells". Current Biology. 27 (17): 2652–2660.e4. Bibcode:2017CBio...27E2652H. doi:10.1016/j.cub.2017.07.033. PMC 5788810. PMID 28844647.
Baker DJ, Wijshake T, Tchkonia T, LeBrasseur NK, Childs BG, van de Sluis B, et al. (November 2011). "Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders". Nature. 479 (7372): 232–236. Bibcode:2011Natur.479..232B. doi:10.1038/nature10600. PMC 3468323. PMID 22048312.
Molofsky AV, Slutsky SG, Joseph NM, He S, Pardal R, Krishnamurthy J, et al. (September 2006). "Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing". Nature. 443 (7110): 448–452. Bibcode:2006Natur.443..448M. doi:10.1038/nature05091. PMC 2586960. PMID 16957738.
Micheli L, D'Andrea G, Ceccarelli M, Ferri A, Scardigli R, Tirone F (2019). "p16Ink4a Prevents the Activation of Aged Quiescent Dentate Gyrus Stem Cells by Physical Exercise". Frontiers in Cellular Neuroscience. 13: 10. doi:10.3389/fncel.2019.00010. PMC 6374340. PMID 30792628.
Li J, Melvin WS, Tsai MD, Muscarella P (April 2004). "The nuclear protein p34SEI-1 regulates the kinase activity of cyclin-dependent kinase 4 in a concentration-dependent manner". Biochemistry. 43 (14): 4394–4399. CiteSeerX 10.1.1.386.140. doi:10.1021/bi035601s. PMID 15065884.
Sugimoto M, Nakamura T, Ohtani N, Hampson L, Hampson IN, Shimamoto A, et al. (November 1999). "Regulation of CDK4 activity by a novel CDK4-binding protein, p34(SEI-1)". Genes & Development. 13 (22): 3027–3033. doi:10.1101/gad.13.22.3027. PMC 317153. PMID 10580009.
Ewing RM, Chu P, Elisma F, Li H, Taylor P, Climie S, et al. (2007). "Large-scale mapping of human protein-protein interactions by mass spectrometry". Molecular Systems Biology. 3: 89. doi:10.1038/msb4100134. PMC 1847948. PMID 17353931.
Fåhraeus R, Paramio JM, Ball KL, Laín S, Lane DP (January 1996). "Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A". Current Biology. 6 (1): 84–91. doi:10.1016/S0960-9822(02)00425-6. hdl:20.500.11820/9e95b5cc-be55-4c50-bfd9-04eb51b3e3f9. PMID 8805225. S2CID 23024663.
Coleman KG, Wautlet BS, Morrissey D, Mulheron J, Sedman SA, Brinkley P, et al. (July 1997). "Identification of CDK4 sequences involved in cyclin D1 and p16 binding". The Journal of Biological Chemistry. 272 (30): 18869–18874. doi:10.1074/jbc.272.30.18869. PMID 9228064.
Russo AA, Tong L, Lee JO, Jeffrey PD, Pavletich NP (September 1998). "Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a". Nature. 395 (6699): 237–243. Bibcode:1998Natur.395..237R. doi:10.1038/26155. PMID 9751050. S2CID 204997058.
Kaldis P, Ojala PM, Tong L, Mäkelä TP, Solomon MJ (December 2001). "CAK-independent activation of CDK6 by a viral cyclin". Molecular Biology of the Cell. 12 (12): 3987–3999. doi:10.1091/mbc.12.12.3987. PMC 60770. PMID 11739795.
Ivanchuk SM, Mondal S, Rutka JT (June 2008). "p14ARF interacts with DAXX: effects on HDM2 and p53". Cell Cycle. 7 (12): 1836–1850. doi:10.4161/cc.7.12.6025. PMID 18583933.
Rizos H, Diefenbach E, Badhwar P, Woodruff S, Becker TM, Rooney RJ, et al. (February 2003). "Association of p14ARF with the p120E4F transcriptional repressor enhances cell cycle inhibition". The Journal of Biological Chemistry. 278 (7): 4981–4989. doi:10.1074/jbc.M210978200. PMID 12446718.
Zhang Y, Wolf GW, Bhat K, Jin A, Allio T, Burkhart WA, et al. (December 2003). "Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway". Molecular and Cellular Biology. 23 (23): 8902–8912. doi:10.1128/MCB.23.23.8902-8912.2003. PMC 262682. PMID 14612427.
Zhang Y, Xiong Y, Yarbrough WG (March 1998). "ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways". Cell. 92 (6): 725–734. doi:10.1016/S0092-8674(00)81401-4. PMID 9529249. S2CID 334187.
Clark PA, Llanos S, Peters G (July 2002). "Multiple interacting domains contribute to p14ARF mediated inhibition of MDM2". Oncogene. 21 (29): 4498–4507. doi:10.1038/sj.onc.1205558. PMID 12085228.
Pomerantz J, Schreiber-Agus N, Liégeois NJ, Silverman A, Alland L, Chin L, et al. (March 1998). "The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53". Cell. 92 (6): 713–723. doi:10.1016/S0092-8674(00)81400-2. PMID 9529248. S2CID 17190271.
Vivo M, Calogero RA, Sansone F, Calabrò V, Parisi T, Borrelli L, et al. (April 2001). "The human tumor suppressor arf interacts with spinophilin/neurabin II, a type 1 protein-phosphatase-binding protein". The Journal of Biological Chemistry. 276 (17): 14161–14169. doi:10.1074/jbc.M006845200. PMID 11278317.

ensembl.org

May2017.archive.ensembl.org

GRCh38: Ensembl release 89: ENSG00000147889 – Ensembl, May 2017
GRCm38: Ensembl release 89: ENSMUSG00000044303 – Ensembl, May 2017

handle.net

hdl.handle.net

Mehanna H, Taberna M, von Buchwald C, Tous S, Brooks J, Mena M, et al. (March 2023). "Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis". The Lancet. Oncology. 24 (3): 239–251. doi:10.1016/s1470-2045(23)00013-x. hdl:2445/198366. PMID 36796393. S2CID 256860640.
Fåhraeus R, Paramio JM, Ball KL, Laín S, Lane DP (January 1996). "Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A". Current Biology. 6 (1): 84–91. doi:10.1016/S0960-9822(02)00425-6. hdl:20.500.11820/9e95b5cc-be55-4c50-bfd9-04eb51b3e3f9. PMID 8805225. S2CID 23024663.

harvard.edu

ui.adsabs.harvard.edu

Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA (April 1994). "Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers". Nature. 368 (6473): 753–756. Bibcode:1994Natur.368..753N. doi:10.1038/368753a0. PMID 8152487. S2CID 13199401.
Serrano M, Hannon GJ, Beach D (December 1993). "A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4". Nature. 366 (6456): 704–707. Bibcode:1993Natur.366..704S. doi:10.1038/366704a0. PMID 8259215. S2CID 4368128.
Krishnamurthy J, Ramsey MR, Ligon KL, Torrice C, Koh A, Bonner-Weir S, et al. (September 2006). "p16INK4a induces an age-dependent decline in islet regenerative potential". Nature. 443 (7110): 453–457. Bibcode:2006Natur.443..453K. doi:10.1038/nature05092. PMID 16957737. S2CID 4402013.
Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, et al. (November 2002). "Role of histone H3 lysine 27 methylation in Polycomb-group silencing". Science. 298 (5595): 1039–1043. Bibcode:2002Sci...298.1039C. doi:10.1126/science.1076997. PMID 12351676. S2CID 6265267.
Hernandez-Segura A, de Jong TV, Melov S, Guryev V, Campisi J, Demaria M (September 2017). "Unmasking Transcriptional Heterogeneity in Senescent Cells". Current Biology. 27 (17): 2652–2660.e4. Bibcode:2017CBio...27E2652H. doi:10.1016/j.cub.2017.07.033. PMC 5788810. PMID 28844647.
Baker DJ, Wijshake T, Tchkonia T, LeBrasseur NK, Childs BG, van de Sluis B, et al. (November 2011). "Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders". Nature. 479 (7372): 232–236. Bibcode:2011Natur.479..232B. doi:10.1038/nature10600. PMC 3468323. PMID 22048312.
Molofsky AV, Slutsky SG, Joseph NM, He S, Pardal R, Krishnamurthy J, et al. (September 2006). "Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing". Nature. 443 (7110): 448–452. Bibcode:2006Natur.443..448M. doi:10.1038/nature05091. PMC 2586960. PMID 16957738.
Russo AA, Tong L, Lee JO, Jeffrey PD, Pavletich NP (September 1998). "Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a". Nature. 395 (6699): 237–243. Bibcode:1998Natur.395..237R. doi:10.1038/26155. PMID 9751050. S2CID 204997058.

nih.gov

pubmed.ncbi.nlm.nih.gov

Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA (April 1994). "Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers". Nature. 368 (6473): 753–756. Bibcode:1994Natur.368..753N. doi:10.1038/368753a0. PMID 8152487. S2CID 13199401.
Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, et al. (July 1995). "Complex structure and regulation of the P16 (MTS1) locus". Cancer Research. 55 (14): 2988–2994. PMID 7606716.
Serrano M, Hannon GJ, Beach D (December 1993). "A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4". Nature. 366 (6456): 704–707. Bibcode:1993Natur.366..704S. doi:10.1038/366704a0. PMID 8259215. S2CID 4368128.
Roussel MF (September 1999). "The INK4 family of cell cycle inhibitors in cancer". Oncogene. 18 (38): 5311–5317. doi:10.1038/sj.onc.1202998. PMID 10498883.
Krishnamurthy J, Ramsey MR, Ligon KL, Torrice C, Koh A, Bonner-Weir S, et al. (September 2006). "p16INK4a induces an age-dependent decline in islet regenerative potential". Nature. 443 (7110): 453–457. Bibcode:2006Natur.443..453K. doi:10.1038/nature05092. PMID 16957737. S2CID 4402013.
Rayess H, Wang MB, Srivatsan ES (April 2012). "Cellular senescence and tumor suppressor gene p16". International Journal of Cancer. 130 (8): 1715–1725. doi:10.1002/ijc.27316. PMC 3288293. PMID 22025288.
Hara E, Smith R, Parry D, Tahara H, Stone S, Peters G (March 1996). "Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence". Molecular and Cellular Biology. 16 (3): 859–867. doi:10.1128/mcb.16.3.859. PMC 231066. PMID 8622687.
Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, et al. (November 2002). "Role of histone H3 lysine 27 methylation in Polycomb-group silencing". Science. 298 (5595): 1039–1043. Bibcode:2002Sci...298.1039C. doi:10.1126/science.1076997. PMID 12351676. S2CID 6265267.
Bracken AP, Kleine-Kohlbrecher D, Dietrich N, Pasini D, Gargiulo G, Beekman C, et al. (March 2007). "The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells". Genes & Development. 21 (5): 525–530. doi:10.1101/gad.415507. PMC 1820894. PMID 17344414.
Liggett WH, Sidransky D (March 1998). "Role of the p16 tumor suppressor gene in cancer". Journal of Clinical Oncology. 16 (3): 1197–1206. doi:10.1200/JCO.1998.16.3.1197. PMID 9508208.
Rocco JW, Sidransky D (March 2001). "p16(MTS-1/CDKN2/INK4a) in cancer progression". Experimental Cell Research. 264 (1): 42–55. doi:10.1006/excr.2000.5149. PMID 11237522.
Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, et al. (September 1994). "Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma". Nature Genetics. 8 (1): 27–32. doi:10.1038/ng0994-27. PMID 7726912. S2CID 23195660.
Bartsch D, Shevlin DW, Tung WS, Kisker O, Wells SA, Goodfellow PJ (November 1995). "Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas". Genes, Chromosomes & Cancer. 14 (3): 189–195. doi:10.1002/gcc.2870140306. PMID 8589035. S2CID 22823227.
Liu L, Lassam NJ, Slingerland JM, Bailey D, Cole D, Jenkins R, et al. (July 1995). "Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma". Oncogene. 11 (2): 405–412. PMID 7624155.
Helgadottir H, Höiom V, Jönsson G, Tuominen R, Ingvar C, Borg A, et al. (August 2014). "High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families". Journal of Medical Genetics. 51 (8): 545–552. doi:10.1136/jmedgenet-2014-102320. PMC 4112445. PMID 24935963.
Igaki H, Sasaki H, Kishi T, Sakamoto H, Tachimori Y, Kato H, et al. (September 1994). "Highly frequent homozygous deletion of the p16 gene in esophageal cancer cell lines". Biochemical and Biophysical Research Communications. 203 (2): 1090–1095. doi:10.1006/bbrc.1994.2294. PMID 8093026.
Puig-Butille JA, Escámez MJ, Garcia-Garcia F, Tell-Marti G, Fabra À, Martínez-Santamaría L, et al. (March 2014). "Capturing the biological impact of CDKN2A and MC1R genes as an early predisposing event in melanoma and non melanoma skin cancer". Oncotarget. 5 (6): 1439–1451. doi:10.18632/oncotarget.1444. PMC 4039222. PMID 24742402.
Khor GH, Froemming GR, Zain RB, Abraham MT, Omar E, Tan SK, et al. (2013). "DNA methylation profiling revealed promoter hypermethylation-induced silencing of p16, DDAH2 and DUSP1 in primary oral squamous cell carcinoma". International Journal of Medical Sciences. 10 (12): 1727–1739. doi:10.7150/ijms.6884. PMC 3805925. PMID 24155659.
Demokan S, Chuang A, Suoğlu Y, Ulusan M, Yalnız Z, Califano JA, et al. (October 2012). "Promoter methylation and loss of p16(INK4a) gene expression in head and neck cancer". Head & Neck. 34 (10): 1470–1475. doi:10.1002/hed.21949. PMID 22106032. S2CID 11512476.
Shaw RJ, Liloglou T, Rogers SN, Brown JS, Vaughan ED, Lowe D, et al. (February 2006). "Promoter methylation of P16, RARbeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing". British Journal of Cancer. 94 (4): 561–568. doi:10.1038/sj.bjc.6602972. PMC 2361183. PMID 16449996.
Sharma G, Mirza S, Prasad CP, Srivastava A, Gupta SD, Ralhan R (April 2007). "Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients". Life Sciences. 80 (20): 1873–1881. doi:10.1016/j.lfs.2007.02.026. PMID 17383681.
Jabłonowski Z, Reszka E, Gromadzińska J, Wąsowicz W, Sosnowski M (June 2011). "Hypermethylation of p16 and DAPK promoter gene regions in patients with non-invasive urinary bladder cancer". Archives of Medical Science. 7 (3): 512–516. doi:10.5114/aoms.2011.23421. PMC 3258754. PMID 22295037.
Xu R, Wang F, Wu L, Wang J, Lu C (January 2013). "A systematic review of hypermethylation of p16 gene in esophageal cancer". Cancer Biomarkers. 13 (4): 215–226. doi:10.3233/CBM-130355. PMID 24240582.
Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. (July 2010). "Human papillomavirus and survival of patients with oropharyngeal cancer". The New England Journal of Medicine. 363 (1): 24–35. doi:10.1056/NEJMoa0912217. PMC 2943767. PMID 20530316.
Lydiatt WM, Patel SG, O'Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, et al. (March 2017). "Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual". CA. 67 (2): 122–137. doi:10.3322/caac.21389. PMID 28128848.
Mehanna H, Taberna M, von Buchwald C, Tous S, Brooks J, Mena M, et al. (March 2023). "Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis". The Lancet. Oncology. 24 (3): 239–251. doi:10.1016/s1470-2045(23)00013-x. hdl:2445/198366. PMID 36796393. S2CID 256860640.
Oguejiofor KK, Hall JS, Mani N, Douglas C, Slevin NJ, Homer J, et al. (November 2013). "The prognostic significance of the biomarker p16 in oropharyngeal squamous cell carcinoma". Clinical Oncology. 25 (11): 630–638. doi:10.1016/j.clon.2013.07.003. PMID 23916365.
Balgkouranidou I, Liloglou T, Lianidou ES (February 2013). "Lung cancer epigenetics: emerging biomarkers". Biomarkers in Medicine. 7 (1): 49–58. doi:10.2217/bmm.12.111. PMID 23387484.
Sinha P, Thorstad WT, Nussenbaum B, Haughey BH, Adkins DR, Kallogjeri D, et al. (January 2014). "Distant metastasis in p16-positive oropharyngeal squamous cell carcinoma: a critical analysis of patterns and outcomes". Oral Oncology. 50 (1): 45–51. doi:10.1016/j.oraloncology.2013.10.007. PMC 3942323. PMID 24211084.
Hwang H, Tse C, Rodriguez S, Gown A, Churg A (May 2014). "p16 FISH deletion in surface epithelial mesothelial proliferations is predictive of underlying invasive mesothelioma". The American Journal of Surgical Pathology. 38 (5): 681–688. doi:10.1097/PAS.0000000000000176. PMID 24503757. S2CID 28068784.
Dreyer JH, Hauck F, Oliveira-Silva M, Barros MH, Niedobitek G (April 2013). "Detection of HPV infection in head and neck squamous cell carcinoma: a practical proposal". Virchows Archiv. 462 (4): 381–389. doi:10.1007/s00428-013-1393-5. PMID 23503925. S2CID 7469046.
Cioffi-Lavina M, Chapman-Fredricks J, Gomez-Fernandez C, Ganjei-Azar P, Manoharan M, Jorda M (July 2010). "P16 expression in squamous cell carcinomas of cervix and bladder". Applied Immunohistochemistry & Molecular Morphology. 18 (4): 344–347. doi:10.1097/PAI.0b013e3181d2bbd7. PMID 20571342. S2CID 5065484.
Hall BM, Balan V, Gleiberman AS, Strom E, Krasnov P, Virtuoso LP, et al. (July 2016). "Aging of mice is associated with p16(Ink4a)- and β-galactosidase-positive macrophage accumulation that can be induced in young mice by senescent cells". Aging. 8 (7): 1294–1315. doi:10.18632/aging.100991. PMC 4993332. PMID 27391570.
Liu Y, Sanoff HK, Cho H, Burd CE, Torrice C, Ibrahim JG, et al. (August 2009). "Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging". Aging Cell. 8 (4): 439–448. doi:10.1111/j.1474-9726.2009.00489.x. PMC 2752333. PMID 19485966.
Hernandez-Segura A, de Jong TV, Melov S, Guryev V, Campisi J, Demaria M (September 2017). "Unmasking Transcriptional Heterogeneity in Senescent Cells". Current Biology. 27 (17): 2652–2660.e4. Bibcode:2017CBio...27E2652H. doi:10.1016/j.cub.2017.07.033. PMC 5788810. PMID 28844647.
Baker DJ, Wijshake T, Tchkonia T, LeBrasseur NK, Childs BG, van de Sluis B, et al. (November 2011). "Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders". Nature. 479 (7372): 232–236. Bibcode:2011Natur.479..232B. doi:10.1038/nature10600. PMC 3468323. PMID 22048312.
Molofsky AV, Slutsky SG, Joseph NM, He S, Pardal R, Krishnamurthy J, et al. (September 2006). "Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing". Nature. 443 (7110): 448–452. Bibcode:2006Natur.443..448M. doi:10.1038/nature05091. PMC 2586960. PMID 16957738.
Micheli L, D'Andrea G, Ceccarelli M, Ferri A, Scardigli R, Tirone F (2019). "p16Ink4a Prevents the Activation of Aged Quiescent Dentate Gyrus Stem Cells by Physical Exercise". Frontiers in Cellular Neuroscience. 13: 10. doi:10.3389/fncel.2019.00010. PMC 6374340. PMID 30792628.
Zhao L, Samuels T, Winckler S, Korgaonkar C, Tompkins V, Horne MC, et al. (January 2003). "Cyclin G1 has growth inhibitory activity linked to the ARF-Mdm2-p53 and pRb tumor suppressor pathways". Molecular Cancer Research. 1 (3): 195–206. PMID 12556559.
Li J, Melvin WS, Tsai MD, Muscarella P (April 2004). "The nuclear protein p34SEI-1 regulates the kinase activity of cyclin-dependent kinase 4 in a concentration-dependent manner". Biochemistry. 43 (14): 4394–4399. CiteSeerX 10.1.1.386.140. doi:10.1021/bi035601s. PMID 15065884.
Sugimoto M, Nakamura T, Ohtani N, Hampson L, Hampson IN, Shimamoto A, et al. (November 1999). "Regulation of CDK4 activity by a novel CDK4-binding protein, p34(SEI-1)". Genes & Development. 13 (22): 3027–3033. doi:10.1101/gad.13.22.3027. PMC 317153. PMID 10580009.
Ewing RM, Chu P, Elisma F, Li H, Taylor P, Climie S, et al. (2007). "Large-scale mapping of human protein-protein interactions by mass spectrometry". Molecular Systems Biology. 3: 89. doi:10.1038/msb4100134. PMC 1847948. PMID 17353931.
Fåhraeus R, Paramio JM, Ball KL, Laín S, Lane DP (January 1996). "Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A". Current Biology. 6 (1): 84–91. doi:10.1016/S0960-9822(02)00425-6. hdl:20.500.11820/9e95b5cc-be55-4c50-bfd9-04eb51b3e3f9. PMID 8805225. S2CID 23024663.
Coleman KG, Wautlet BS, Morrissey D, Mulheron J, Sedman SA, Brinkley P, et al. (July 1997). "Identification of CDK4 sequences involved in cyclin D1 and p16 binding". The Journal of Biological Chemistry. 272 (30): 18869–18874. doi:10.1074/jbc.272.30.18869. PMID 9228064.
Russo AA, Tong L, Lee JO, Jeffrey PD, Pavletich NP (September 1998). "Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a". Nature. 395 (6699): 237–243. Bibcode:1998Natur.395..237R. doi:10.1038/26155. PMID 9751050. S2CID 204997058.
Kaldis P, Ojala PM, Tong L, Mäkelä TP, Solomon MJ (December 2001). "CAK-independent activation of CDK6 by a viral cyclin". Molecular Biology of the Cell. 12 (12): 3987–3999. doi:10.1091/mbc.12.12.3987. PMC 60770. PMID 11739795.
Ivanchuk SM, Mondal S, Rutka JT (June 2008). "p14ARF interacts with DAXX: effects on HDM2 and p53". Cell Cycle. 7 (12): 1836–1850. doi:10.4161/cc.7.12.6025. PMID 18583933.
Rizos H, Diefenbach E, Badhwar P, Woodruff S, Becker TM, Rooney RJ, et al. (February 2003). "Association of p14ARF with the p120E4F transcriptional repressor enhances cell cycle inhibition". The Journal of Biological Chemistry. 278 (7): 4981–4989. doi:10.1074/jbc.M210978200. PMID 12446718.
Zhang Y, Wolf GW, Bhat K, Jin A, Allio T, Burkhart WA, et al. (December 2003). "Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway". Molecular and Cellular Biology. 23 (23): 8902–8912. doi:10.1128/MCB.23.23.8902-8912.2003. PMC 262682. PMID 14612427.
Zhang Y, Xiong Y, Yarbrough WG (March 1998). "ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways". Cell. 92 (6): 725–734. doi:10.1016/S0092-8674(00)81401-4. PMID 9529249. S2CID 334187.
Clark PA, Llanos S, Peters G (July 2002). "Multiple interacting domains contribute to p14ARF mediated inhibition of MDM2". Oncogene. 21 (29): 4498–4507. doi:10.1038/sj.onc.1205558. PMID 12085228.
Pomerantz J, Schreiber-Agus N, Liégeois NJ, Silverman A, Alland L, Chin L, et al. (March 1998). "The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53". Cell. 92 (6): 713–723. doi:10.1016/S0092-8674(00)81400-2. PMID 9529248. S2CID 17190271.
Vivo M, Calogero RA, Sansone F, Calabrò V, Parisi T, Borrelli L, et al. (April 2001). "The human tumor suppressor arf interacts with spinophilin/neurabin II, a type 1 protein-phosphatase-binding protein". The Journal of Biological Chemistry. 276 (17): 14161–14169. doi:10.1074/jbc.M006845200. PMID 11278317.

ncbi.nlm.nih.gov

"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Entrez Gene: CDKN2A cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)".
Rayess H, Wang MB, Srivatsan ES (April 2012). "Cellular senescence and tumor suppressor gene p16". International Journal of Cancer. 130 (8): 1715–1725. doi:10.1002/ijc.27316. PMC 3288293. PMID 22025288.
Hara E, Smith R, Parry D, Tahara H, Stone S, Peters G (March 1996). "Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence". Molecular and Cellular Biology. 16 (3): 859–867. doi:10.1128/mcb.16.3.859. PMC 231066. PMID 8622687.
Bracken AP, Kleine-Kohlbrecher D, Dietrich N, Pasini D, Gargiulo G, Beekman C, et al. (March 2007). "The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells". Genes & Development. 21 (5): 525–530. doi:10.1101/gad.415507. PMC 1820894. PMID 17344414.
Helgadottir H, Höiom V, Jönsson G, Tuominen R, Ingvar C, Borg A, et al. (August 2014). "High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families". Journal of Medical Genetics. 51 (8): 545–552. doi:10.1136/jmedgenet-2014-102320. PMC 4112445. PMID 24935963.
Puig-Butille JA, Escámez MJ, Garcia-Garcia F, Tell-Marti G, Fabra À, Martínez-Santamaría L, et al. (March 2014). "Capturing the biological impact of CDKN2A and MC1R genes as an early predisposing event in melanoma and non melanoma skin cancer". Oncotarget. 5 (6): 1439–1451. doi:10.18632/oncotarget.1444. PMC 4039222. PMID 24742402.
Khor GH, Froemming GR, Zain RB, Abraham MT, Omar E, Tan SK, et al. (2013). "DNA methylation profiling revealed promoter hypermethylation-induced silencing of p16, DDAH2 and DUSP1 in primary oral squamous cell carcinoma". International Journal of Medical Sciences. 10 (12): 1727–1739. doi:10.7150/ijms.6884. PMC 3805925. PMID 24155659.
Shaw RJ, Liloglou T, Rogers SN, Brown JS, Vaughan ED, Lowe D, et al. (February 2006). "Promoter methylation of P16, RARbeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing". British Journal of Cancer. 94 (4): 561–568. doi:10.1038/sj.bjc.6602972. PMC 2361183. PMID 16449996.
Jabłonowski Z, Reszka E, Gromadzińska J, Wąsowicz W, Sosnowski M (June 2011). "Hypermethylation of p16 and DAPK promoter gene regions in patients with non-invasive urinary bladder cancer". Archives of Medical Science. 7 (3): 512–516. doi:10.5114/aoms.2011.23421. PMC 3258754. PMID 22295037.
Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. (July 2010). "Human papillomavirus and survival of patients with oropharyngeal cancer". The New England Journal of Medicine. 363 (1): 24–35. doi:10.1056/NEJMoa0912217. PMC 2943767. PMID 20530316.
Sinha P, Thorstad WT, Nussenbaum B, Haughey BH, Adkins DR, Kallogjeri D, et al. (January 2014). "Distant metastasis in p16-positive oropharyngeal squamous cell carcinoma: a critical analysis of patterns and outcomes". Oral Oncology. 50 (1): 45–51. doi:10.1016/j.oraloncology.2013.10.007. PMC 3942323. PMID 24211084.
Hall BM, Balan V, Gleiberman AS, Strom E, Krasnov P, Virtuoso LP, et al. (July 2016). "Aging of mice is associated with p16(Ink4a)- and β-galactosidase-positive macrophage accumulation that can be induced in young mice by senescent cells". Aging. 8 (7): 1294–1315. doi:10.18632/aging.100991. PMC 4993332. PMID 27391570.
Liu Y, Sanoff HK, Cho H, Burd CE, Torrice C, Ibrahim JG, et al. (August 2009). "Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging". Aging Cell. 8 (4): 439–448. doi:10.1111/j.1474-9726.2009.00489.x. PMC 2752333. PMID 19485966.
Hernandez-Segura A, de Jong TV, Melov S, Guryev V, Campisi J, Demaria M (September 2017). "Unmasking Transcriptional Heterogeneity in Senescent Cells". Current Biology. 27 (17): 2652–2660.e4. Bibcode:2017CBio...27E2652H. doi:10.1016/j.cub.2017.07.033. PMC 5788810. PMID 28844647.
Baker DJ, Wijshake T, Tchkonia T, LeBrasseur NK, Childs BG, van de Sluis B, et al. (November 2011). "Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders". Nature. 479 (7372): 232–236. Bibcode:2011Natur.479..232B. doi:10.1038/nature10600. PMC 3468323. PMID 22048312.
Molofsky AV, Slutsky SG, Joseph NM, He S, Pardal R, Krishnamurthy J, et al. (September 2006). "Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing". Nature. 443 (7110): 448–452. Bibcode:2006Natur.443..448M. doi:10.1038/nature05091. PMC 2586960. PMID 16957738.
Micheli L, D'Andrea G, Ceccarelli M, Ferri A, Scardigli R, Tirone F (2019). "p16Ink4a Prevents the Activation of Aged Quiescent Dentate Gyrus Stem Cells by Physical Exercise". Frontiers in Cellular Neuroscience. 13: 10. doi:10.3389/fncel.2019.00010. PMC 6374340. PMID 30792628.
Sugimoto M, Nakamura T, Ohtani N, Hampson L, Hampson IN, Shimamoto A, et al. (November 1999). "Regulation of CDK4 activity by a novel CDK4-binding protein, p34(SEI-1)". Genes & Development. 13 (22): 3027–3033. doi:10.1101/gad.13.22.3027. PMC 317153. PMID 10580009.
Ewing RM, Chu P, Elisma F, Li H, Taylor P, Climie S, et al. (2007). "Large-scale mapping of human protein-protein interactions by mass spectrometry". Molecular Systems Biology. 3: 89. doi:10.1038/msb4100134. PMC 1847948. PMID 17353931.
Kaldis P, Ojala PM, Tong L, Mäkelä TP, Solomon MJ (December 2001). "CAK-independent activation of CDK6 by a viral cyclin". Molecular Biology of the Cell. 12 (12): 3987–3999. doi:10.1091/mbc.12.12.3987. PMC 60770. PMID 11739795.
Zhang Y, Wolf GW, Bhat K, Jin A, Allio T, Burkhart WA, et al. (December 2003). "Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway". Molecular and Cellular Biology. 23 (23): 8902–8912. doi:10.1128/MCB.23.23.8902-8912.2003. PMC 262682. PMID 14612427.

nihr.ac.uk

evidence.nihr.ac.uk

"Testing for both HPV and p16 can give more precise prognoses in oropharyngeal (throat) cancer". NIHR Evidence. 2023. doi:10.3310/nihrevidence_59749. S2CID 261791439.

omim.org

Hamosh A. "Cyclin-dependent kinase inhibitor 2A; CDKN2A". OMIM. Retrieved 10 December 2013.

pathologyoutlines.com

Image by Mikael Häggström, MD. Reference for terminology: Anjelica Hodgson, M.D., Carlos Parra-Herran, M.D. "p16". Pathology Outlines.{{cite web}}: CS1 maint: multiple names: authors list (link) Last staff update: 25 January 2024

psu.edu

citeseerx.ist.psu.edu

Li J, Melvin WS, Tsai MD, Muscarella P (April 2004). "The nuclear protein p34SEI-1 regulates the kinase activity of cyclin-dependent kinase 4 in a concentration-dependent manner". Biochemistry. 43 (14): 4394–4399. CiteSeerX 10.1.1.386.140. doi:10.1021/bi035601s. PMID 15065884.

semanticscholar.org

api.semanticscholar.org

Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA (April 1994). "Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers". Nature. 368 (6473): 753–756. Bibcode:1994Natur.368..753N. doi:10.1038/368753a0. PMID 8152487. S2CID 13199401.
Serrano M, Hannon GJ, Beach D (December 1993). "A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4". Nature. 366 (6456): 704–707. Bibcode:1993Natur.366..704S. doi:10.1038/366704a0. PMID 8259215. S2CID 4368128.
Krishnamurthy J, Ramsey MR, Ligon KL, Torrice C, Koh A, Bonner-Weir S, et al. (September 2006). "p16INK4a induces an age-dependent decline in islet regenerative potential". Nature. 443 (7110): 453–457. Bibcode:2006Natur.443..453K. doi:10.1038/nature05092. PMID 16957737. S2CID 4402013.
Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, et al. (November 2002). "Role of histone H3 lysine 27 methylation in Polycomb-group silencing". Science. 298 (5595): 1039–1043. Bibcode:2002Sci...298.1039C. doi:10.1126/science.1076997. PMID 12351676. S2CID 6265267.
Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, et al. (September 1994). "Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma". Nature Genetics. 8 (1): 27–32. doi:10.1038/ng0994-27. PMID 7726912. S2CID 23195660.
Bartsch D, Shevlin DW, Tung WS, Kisker O, Wells SA, Goodfellow PJ (November 1995). "Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas". Genes, Chromosomes & Cancer. 14 (3): 189–195. doi:10.1002/gcc.2870140306. PMID 8589035. S2CID 22823227.
Demokan S, Chuang A, Suoğlu Y, Ulusan M, Yalnız Z, Califano JA, et al. (October 2012). "Promoter methylation and loss of p16(INK4a) gene expression in head and neck cancer". Head & Neck. 34 (10): 1470–1475. doi:10.1002/hed.21949. PMID 22106032. S2CID 11512476.
Mehanna H, Taberna M, von Buchwald C, Tous S, Brooks J, Mena M, et al. (March 2023). "Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis". The Lancet. Oncology. 24 (3): 239–251. doi:10.1016/s1470-2045(23)00013-x. hdl:2445/198366. PMID 36796393. S2CID 256860640.
"Testing for both HPV and p16 can give more precise prognoses in oropharyngeal (throat) cancer". NIHR Evidence. 2023. doi:10.3310/nihrevidence_59749. S2CID 261791439.
Hwang H, Tse C, Rodriguez S, Gown A, Churg A (May 2014). "p16 FISH deletion in surface epithelial mesothelial proliferations is predictive of underlying invasive mesothelioma". The American Journal of Surgical Pathology. 38 (5): 681–688. doi:10.1097/PAS.0000000000000176. PMID 24503757. S2CID 28068784.
Dreyer JH, Hauck F, Oliveira-Silva M, Barros MH, Niedobitek G (April 2013). "Detection of HPV infection in head and neck squamous cell carcinoma: a practical proposal". Virchows Archiv. 462 (4): 381–389. doi:10.1007/s00428-013-1393-5. PMID 23503925. S2CID 7469046.
Cioffi-Lavina M, Chapman-Fredricks J, Gomez-Fernandez C, Ganjei-Azar P, Manoharan M, Jorda M (July 2010). "P16 expression in squamous cell carcinomas of cervix and bladder". Applied Immunohistochemistry & Molecular Morphology. 18 (4): 344–347. doi:10.1097/PAI.0b013e3181d2bbd7. PMID 20571342. S2CID 5065484.
Fåhraeus R, Paramio JM, Ball KL, Laín S, Lane DP (January 1996). "Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A". Current Biology. 6 (1): 84–91. doi:10.1016/S0960-9822(02)00425-6. hdl:20.500.11820/9e95b5cc-be55-4c50-bfd9-04eb51b3e3f9. PMID 8805225. S2CID 23024663.
Russo AA, Tong L, Lee JO, Jeffrey PD, Pavletich NP (September 1998). "Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a". Nature. 395 (6699): 237–243. Bibcode:1998Natur.395..237R. doi:10.1038/26155. PMID 9751050. S2CID 204997058.
Zhang Y, Xiong Y, Yarbrough WG (March 1998). "ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways". Cell. 92 (6): 725–734. doi:10.1016/S0092-8674(00)81401-4. PMID 9529249. S2CID 334187.
Pomerantz J, Schreiber-Agus N, Liégeois NJ, Silverman A, Alland L, Chin L, et al. (March 1998). "The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53". Cell. 92 (6): 713–723. doi:10.1016/S0092-8674(00)81400-2. PMID 9529248. S2CID 17190271.